rofecoxib has been researched along with Brain Thrombosis in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rofecoxib was withdrawn from the market worldwide because of concerns relating to cardiovascular safety." | 1.33 | Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. ( Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison-Woolrych, M | 1 |
| Herbison, P | 1 |
| McLean, R | 1 |
| Ashton, J | 1 |
| Slattery, J | 1 |
1 other study available for rofecoxib and Brain Thrombosis
| Article | Year |
|---|---|
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; F | 2005 |